Bio-Rad Laboratories reported second-quarter 2026 total net sales of approximately $651 million, essentially flat on a reported basis and down 1.9 percent on a currency-neutral basis. Clinical Diagnostics sales were approximately $399 million, an increase of 2.6 percent on a reported basis and 8.3 percent on a currency-neutral basis, led by quality systems, diabetes, and blood typing products. Life Science segment revenue was $252 million, a 5.1 percent currency-neutral decrease driven by academic research challenges and a difficult comparison in process chromatography. Digital PCR instrument revenue increased more than 20 percent, reflecting competitive wins and conversions from traditional qPCR platforms. Non-GAAP operating margin was 12.5 percent, a sequential improvement from 6.6 percent in the first quarter, and non-GAAP net income was $70.2 million, or $2.62 per diluted share. The company reaffirmed its full-year 2026 guidance for currency-neutral revenue growth between minus 3 percent and plus 0.5 percent and non-GAAP operating margin of 10 to 12 percent, while announcing a restructuring expected to yield $30 million to $35 million in annualized net savings by the end of 2027.
Bio-Rad Laboratories IncMixed Q2 results: Clinical Diagnostics growth offset by Life Science softness, with restructuring and reaffirmed guidance.
